Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Share-based Compensation (2021 - 2025)

Rani Therapeutics Holdings has reported Share-based Compensation over the past 5 years, most recently at $2.2 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $2.2 million for Q4 2025, down 43.92% from a year ago — trailing twelve months through Dec 2025 was $11.8 million (down 26.41% YoY), and the annual figure for FY2025 was $11.8 million, down 26.41%.
  • Share-based Compensation for Q4 2025 was $2.2 million at Rani Therapeutics Holdings, down from $2.3 million in the prior quarter.
  • Over the last five years, Share-based Compensation for RANI hit a ceiling of $18.7 million in Q3 2021 and a floor of $282000.0 in Q2 2021.
  • Median Share-based Compensation over the past 5 years was $4.0 million (2022), compared with a mean of $4.3 million.
  • Peak annual rise in Share-based Compensation hit 1309.93% in 2022, while the deepest fall reached 76.45% in 2022.
  • Rani Therapeutics Holdings' Share-based Compensation stood at $3.2 million in 2021, then skyrocketed by 42.15% to $4.5 million in 2022, then dropped by 0.29% to $4.5 million in 2023, then dropped by 11.03% to $4.0 million in 2024, then tumbled by 43.92% to $2.2 million in 2025.
  • The last three reported values for Share-based Compensation were $2.2 million (Q4 2025), $2.3 million (Q3 2025), and $3.3 million (Q2 2025) per Business Quant data.